insights_auto
Why is AXGN down ५.०६%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
US$ ४८.७५
arrow_downward
-५.०६%(-२.६०) 1D
US$ ४८.५५
arrow_downward
-०.४१% (-०.२०)todayPre-market
Closed: नोभेम्बर ५, १६:००:०१ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
US$ ५१.६२
High
US$ ५१.८५
Low
US$ ४७.५७
Mkt. cap
२.९१ अरब
Avg. vol.
१७.८० लाख
Volume
३७५.००
52-wk high
US$ ५२.९१
52-wk low
US$ २३.००
EPS
-US$ ०.६८
Beta
१.२१
Shares outstanding
५.९७ करोड
No. of employees
६२२
Open
US$ ५१.६२
High
US$ ५१.८५
Low
US$ ४७.५७
Mkt. cap
२.९१ अरब
Avg. vol.
१७.८० लाख
Volume
३७५.००
52-wk high
US$ ५२.९१
52-wk low
US$ २३.००
EPS
-US$ ०.६८
Beta
१.२१
Shares outstanding
५.९७ करोड
No. of employees
६२२
News stories
From web sources and news partners
ChartMill
·
३८ मिनेट पहिले
Octave Intelligence (NASDAQ:OCTV) Breakout Setup Shows Technical Strength
Bloomberg.com
·
२८ मिनेट पहिले
Fast-Money Systematic Funds Stoked $2.3 Trillion Tech-Stock Rout
Seeking Alpha
·
१ घण्टा पहिले
SPX/Gold Ratio: Dome Of Doom
Fox Business
·
१४ घण्टा पहिले
Stocks plunge as Dem midterm sweep fuels AI regulatory concerns
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees६२२
Founded२००२
HeadquartersAlachua, फ्लोरिडा, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websiteaxogeninc.com